Search

Your search keyword '"Skarnovich, Maksim O."' showing total 8 results
Start Over Author "Skarnovich, Maksim O."
8 results on '"Skarnovich, Maksim O."'

1. The First Case of Zika Virus Disease in Guinea: Description, Virus Isolation, Sequencing, and Seroprevalence in Local Population

Author

Bayandin, Roman B., primary, Makenov, Marat T., additional, Boumbaly, Sanaba, additional, Stukolova, Olga A., additional, Gladysheva, Anastasia V., additional, Shipovalov, Andrey V., additional, Skarnovich, Maksim O., additional, Camara, Ousmane, additional, Toure, Aboubacar Hady, additional, Svyatchenko, Victor A., additional, Shvalov, Alexander N., additional, Ternovoi, Vladimir A., additional, Boiro, Mamadou Y., additional, Agafonov, Alexander P., additional, and Karan, Lyudmila S., additional

Published
2023
Full Text
View/download PDF

2. The First Case of Zika Virus Disease in Guinea: Description, Virus Isolation, Sequencing and Seroprevalence in Local Population

Author

Bayandin, Roman, primary, Makenov, Marat T., additional, Boumbaly, Sanaba, additional, Stukolova, Olga A., additional, Gladysheva, Anastasia V., additional, Shipovalov, Andrey V., additional, Skarnovich, Maksim O., additional, Camara, Ousmane, additional, Toure, Aboubacar Hady, additional, Svyatchenko, Victor A., additional, Shvalov, Alexander N., additional, Ternovoi, Vladimir A., additional, Boiro, Mamadou Y., additional, Agafonov, Alexander P., additional, and Karan, Lyudmila S., additional

Published
2023
Full Text
View/download PDF

3. Safety and Pharmacokinetics of the Substance of the Anti-Smallpox Drug NIOCH-14 after Oral Administration to Laboratory Animals

Author

Shishkina, Larisa N., primary, Mazurkov, Oleg Yu., additional, Bormotov, Nikolai I., additional, Skarnovich, Maksim O., additional, Serova, Olga A., additional, Mazurkova, Natalia A., additional, Skarnovich, Maria A., additional, Chernonosov, Alexander A., additional, Selivanov, Boris A., additional, Tikhonov, Alexey Ya., additional, Gamaley, Svetlana G., additional, Shimina, Galina G., additional, Sysoyeva, Galina M., additional, Taranov, Oleg S., additional, Danilenko, Elena D., additional, Agafonov, Alexander P., additional, and Maksyutov, Rinat A., additional

Published
2023
Full Text
View/download PDF

4. Genome Features and In Vitro Activity against Influenza A and SARS-CoV-2 Viruses of Six Probiotic Strains

Author

Soloveva, Irina V., primary, Ilyicheva, Tatyana N., additional, Marchenko, Vasiliy Yu., additional, Pyankov, Oleg V., additional, Tochilina, Anna G., additional, Belova, Irina V., additional, Zhirnov, Vladimir A., additional, Bormotov, Nikolay I., additional, Skarnovich, Maksim O., additional, Durymanov, Aleksander G., additional, Molodtsova, Svetlana B., additional, Filippova, Ekaterina I., additional, Ovchinnikova, Alena S., additional, Magerramova, Anastasia V., additional, Ryzhikov, Alexander B., additional, and Maksyutov, Rinat A., additional

Published
2021
Full Text
View/download PDF

6. New effective chemically synthesized anti-smallpox compound NIOCH-14

Author

Mazurkov, Oleg Yu., primary, Kabanov, Alexey S., additional, Shishkina, Larisa N., additional, Sergeev, Alexander A., additional, Skarnovich, Maksim O., additional, Bormotov, Nikolay I., additional, Skarnovich, Maria A., additional, Ovchinnikova, Alena S., additional, Titova, Ksenya A., additional, Galahova, Darya O., additional, Bulychev, Leonid E., additional, Sergeev, Artemiy A., additional, Taranov, Oleg S., additional, Selivanov, Boris A., additional, Tikhonov, Alexey Ya., additional, Zavjalov, Evgenii L., additional, Agafonov, Alexander P., additional, and Sergeev, Alexander N., additional

Published
2016
Full Text
View/download PDF

8. Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

Author

Skarnovich MA, Emelyanova AG, Petrova NV, Borshcheva AA, Gorbunov EA, Mazurkov OY, Skarnovich MO, Tarasov SA, Shishkina LN, and Epstein OI

Subjects
Animals, CD4 Antigens antagonists & inhibitors, CD4 Antigens immunology, Drug Administration Schedule, Drug Dosage Calculations, Female, Histamine immunology, Influenza A Virus, H3N2 Subtype growth & development, Influenza A Virus, H3N2 Subtype immunology, Interferon-gamma antagonists & inhibitors, Interferon-gamma immunology, Longevity immunology, Lung drug effects, Lung immunology, Lung virology, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections mortality, Orthomyxoviridae Infections virology, Oseltamivir pharmacology, Survival Analysis, Treatment Outcome, Viral Load drug effects, Antibodies pharmacology, Antiviral Agents pharmacology, Immunologic Factors pharmacology, Influenza A Virus, H3N2 Subtype drug effects, Orthomyxoviridae Infections drug therapy
Abstract

Background: The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for new effective treatments. One of them is ergoferon, a drug containing combined polyclonal antibodies - anti-interferon gamma, anti-CD4 receptor and anti-histamine - in released-active form. The purpose of the study was to assess ergoferon antiviral efficacy in mice challenged with the A/Aichi/2/68 (H3N2) influenza virus., Methods: The virus was inoculated intranasally at a 90% lethal dose. Ergoferon was administered at 0.4 ml/day per os in a preventive and therapeutic regimen - daily for 5 days prior to and for 16 days after the challenge. The reference product, Tamiflu (oseltamivir), was used as a positive control treatment - at 20 mg/kg/day for 5 days after the challenge. Mice in the negative control group received distilled water which had been utilized for test sample preparation; untreated control animals received no treatment. Antiviral efficacy was assessed by an increase in survival rate, average life expectancy and virus titre reduction in the challenged mouse lungs., Results: Survival rate and average life expectancy values were increased significantly in groups treated with ergoferon and Tamiflu, as compared with controls. Lung virus titres were reduced in these groups as observed on days 2 and 4 post-inoculation., Conclusions: Ergoferon demonstrated antiviral activity by reducing the severity and duration of the major signs of induced influenza infection.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results